Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England
M Miret, A Anderson, P Hindocha, L Cirneanu… - Leukemia research, 2023 - Elsevier
Background Treatments for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL)
may be associated with an increased risk of second primary malignancies (SPMs). Currently …
may be associated with an increased risk of second primary malignancies (SPMs). Currently …
Chemotherapy-free management of follicular and marginal zone lymphoma
TA Ollila, AJ Olszewski - Cancer Management and Research, 2021 - Taylor & Francis
Many patients with follicular (FL) or marginal zone lymphoma (MZL) are not eligible to
receive immunochemotherapy due to advanced age or comorbidities. Recent innovations in …
receive immunochemotherapy due to advanced age or comorbidities. Recent innovations in …
Advances in the treatment of relapsed/refractory marginal zone lymphoma
H Wang, X Wan, Y Zhang, J Guo, O Bai - Frontiers in Oncology, 2024 - frontiersin.org
Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-
Hodgkin's lymphoma, accounting for 5–15% of non-Hodgkin's lymphoma cases. Patients …
Hodgkin's lymphoma, accounting for 5–15% of non-Hodgkin's lymphoma cases. Patients …
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.
DM Stephens, JR Brown, S Ma, M Wang, CD Moreno… - 2023 - ascopubs.org
7538 Background: Continuous therapy with once-daily ibrutinib (Ibr) is associated with long-
term PFS in pts with B-cell malignancies. Dose reduction is a potential AE management …
term PFS in pts with B-cell malignancies. Dose reduction is a potential AE management …
Targeted agents in the treatment of indolent b-cell non-hodgkin lymphomas
Simple Summary New therapies for lymphoma continue to be developed at a rapid rate,
including for the indolent lymphomas. While traditional cytotoxic chemotherapy remains an …
including for the indolent lymphomas. While traditional cytotoxic chemotherapy remains an …
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 …
Background Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐
Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because …
Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because …
Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation …
M Chen, S Du, Y Cheng, X Zhu, Y Wang, S Shu… - International …, 2024 - Elsevier
Objectives HWH486 inhibits Bruton's tyrosine kinase and therefore shows promise as a
treatment against rheumatoid arthritis and chronic spontaneous urticaria. This phase I trial …
treatment against rheumatoid arthritis and chronic spontaneous urticaria. This phase I trial …
N‐acetyltransferase 10 facilitates tumorigenesis of diffuse large B‐cell lymphoma by regulating AMPK/mTOR signalling through N4‐acetylcytidine modification of …
M Ding, Z Yu, T Lu, S Hu, X Zhou… - Clinical and …, 2024 - Wiley Online Library
Background Accumulating studies suggested that posttranscriptional modifications exert a
vital role in the tumorigenesis of diffuse large B‐cell lymphoma (DLBCL). N4‐acetylcytidine …
vital role in the tumorigenesis of diffuse large B‐cell lymphoma (DLBCL). N4‐acetylcytidine …
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's …
P Panayiotidis, G Tumyan, C Thieblemont… - Leukemia & …, 2022 - Taylor & Francis
We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab
(eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with …
(eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with …
[HTML][HTML] IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
MC Pirosa, M Sassone, B Kiesewetter… - …, 2023 - ncbi.nlm.nih.gov
Currently, there is not a single standard of care for patients with relapsed/refractory (R/R)
marginal zone lymphoma (MZL), in whom avoiding overtreatment and superfluous toxicity is …
marginal zone lymphoma (MZL), in whom avoiding overtreatment and superfluous toxicity is …